Rare Disease Therapeutics, Inc.
Franklin, TN
- UEI
- M7B1ABSZJKX8
- CAGE
- 5CMX0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 2550 Meridian Blvd #150, Franklin, TN 37067, USA
- Website
- raretx.com
- Founded
- 1991
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $36,000 |
| FY2025 | $36,193 |
| FY2024 | $124,030 |
| FY2023 | -$26,861 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $36,000 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Biocryst Pharmaceuticals Inc. | Durham, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Botanix SB Inc. | Phoenix, AZ | 325412 Pharmaceutical Preparation Manufacturing |
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Hygen Pharmaceuticals Inc. | Redmond, WA | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
About the company
Rare Disease Therapeutics, Inc., a woman-owned small business headquartered in Franklin, Tennessee, supplies specialty pharmaceutical products—primarily ANASCORP scorpion antivenom injections and orphan drugs for rare disease treatment—to federal healthcare agencies as a prime contractor, operating exclusively through GSA Schedule contracts and derivative blanket purchase agreements without subcontracting exposure.
Rare Disease Therapeutics operates as a for-profit Subchapter S corporation under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and competes full-and-open without set-aside designations. The company's entire federal footprint (100% of recent awards) flows through its GSA Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), with task orders placed by healthcare agencies serving civilian populations. The vendor's customer concentration skews heavily toward Indian Health Service work by order count but shifts dramatically toward the Department of Veterans Affairs by potential value. The Indian Health Service accounts for 45 of 56 total awards with $2 million in combined potential value, primarily ANASCORP delivery orders and BPA calls to IHS clinics serving tribal nations in Arizona. Conversely, the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 holds only 4 awards but carries $24.6 million in combined potential value, anchored by a $11.119 million Federal Supply Schedule contract awarded on September 29, 2026, running through September 28, 2031. The VA National Acquisition Center separately awarded a $250 thousand single-award BPA (ultimate completion May 31, 2027) for specialty pharmaceutical access. Smithsonian Institution and additional VA regional networks round out the customer set with minimal order volume and value.
Recent award activity shows modest growth—two awards in 2022 to five in 2025—with only one award (valued at $82 thousand) facing ultimate completion within the next twenty-four months, presenting minimal near-term recompete exposure. The company's 56 prime awards cluster into 62 task orders under the single parent vehicle (Pharmaceuticals and Drugs GSA Schedule), generating $3.7 million in combined potential value against task orders, while the broader IDV portfolio carries substantially higher ceilings. Combined obligated dollars total $1.3 million across all awards, representing 5% utilization against $28 million in combined potential value, reflecting the indefinite-delivery structure of the underlying vehicles and the vendor's positioning as a catalog supplier rather than a project-based contractor. Rare Disease Therapeutics' capability footprint is narrowly specialized: ANASCORP antivenom distribution to federal healthcare facilities, orphan drug logistics, and medical countermeasure supply chain support to veteran and tribal health systems, with no prime work in defense, intelligence, or civilian IT modernization.
Quick answers
Is Rare Disease Therapeutics, Inc. registered in SAM.gov?
Yes. Rare Disease Therapeutics, Inc.'s SAM.gov registration is active through May 13, 2027.
Which contract vehicles does Rare Disease Therapeutics, Inc. hold?
Rare Disease Therapeutics, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Rare Disease Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $36,193 to Rare Disease Therapeutics, Inc. in fiscal year 2025 and $169,361 in fiscal years 2023 through 2027.
What is Rare Disease Therapeutics, Inc.'s most recent federal award?
Rare Disease Therapeutics, Inc.'s most recent federal contract award is Anavorx distribution LLC, anascorp antivenom, wrsu pharmacy dept, do/to 26F80033 (75H71226F80033), from Indian Health Service, on June 15, 2026.
On GovTribe
See Rare Disease Therapeutics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors